Adagio Medical Holdings (ADGM)
NASDAQ:ADGM
Want to see ADGM full AI Analyst Report?
ADGM Stock Chart & Stats
$1.08
-$0.11(-9.46%)
At close: 4:00 PM EST
$1.08
-$0.11(-9.46%)
Day’s Range― - ―
52-Week Range$0.74 - $2.58
Previous Close$1.04
Volume669.05K
Average Volume (3M)152.12K
Market Cap
$31.76M
Enterprise Value$28.25M
Total Cash (Recent Filing)$17.11M
Total Debt (Recent Filing)$21.76M
Price to Earnings (P/E)―
Beta-0.39
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding22,210,459
10 Day Avg. Volume84,483
30 Day Avg. Volume152,119
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.39
Price to Sales (P/S)0.00
P/FCF Ratio-0.89
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-30.67
Enterprise Value/Ebitda-1.15
Forecast
1Y Price Target
$3.50Price Target Upside224.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory IDE ExpansionThe FDA IDE expansion institutionalizes clinical evaluation of the next‑generation vCLAS system and enables a prospective multi‑center sub-study. This creates a durable pathway to regulatory validation and clinical evidence, which is prerequisite to commercial adoption and sustained market entry over months to years.
Differentiated TechnologyThe ultra‑low temperature, single‑freeze catheter architecture built on the ULTA platform suggests a structural product differentiation that can shorten procedure time, improve lesion control and manufacturability. If clinical outcomes mirror preclinical claims, this supports sustainable competitive advantage in EP device workflows.
Improving Cash Burn TrendReported reduction in losses and burn in 2025, plus a shift to positive equity, indicates improving financial stamina and management control. This trend, if maintained, reduces financing frequency and supports a longer runway to commercialization — an important durable improvement versus prior balance‑sheet stress.
Bears Say
No Commercial RevenueZero reported revenue in 2025 signals absence of commercial traction and means the company remains dependent on clinical progress and external financing. Lack of product revenues prevents internal funding of R&D and scale-up, leaving long‑term viability contingent on successful trial outcomes and market entry.
Sustained UnprofitabilityPersistent negative gross profit and operating losses demonstrate that unit economics are unproven. Until the company achieves positive gross margins and consistent operating profit, returns on invested capital remain uncertain and scaling commercialization risks deepening losses rather than producing sustainable margins.
Elevated Leverage & Cash BurnDebt exceeding equity and consecutive years of negative operating and free cash flow indicate limited financial flexibility. Elevated leverage increases refinancing risk and interest burden, while ongoing burn forces dependence on external capital, which can dilute shareholders and constrain long‑term strategic choices.
Adagio Medical Holdings News
ADGM FAQ
What was Adagio Medical Holdings’s price range in the past 12 months?
Adagio Medical Holdings lowest stock price was $0.74 and its highest was $2.58 in the past 12 months.
What is Adagio Medical Holdings’s market cap?
Adagio Medical Holdings’s market cap is $31.76M.
When is Adagio Medical Holdings’s upcoming earnings report date?
Adagio Medical Holdings’s upcoming earnings report date is May 14, 2026 which is in 25 days.
How were Adagio Medical Holdings’s earnings last quarter?
Adagio Medical Holdings released its earnings results on Apr 06, 2026. The company reported -$0.21 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.1.
Is Adagio Medical Holdings overvalued?
According to Wall Street analysts Adagio Medical Holdings’s price is currently Undervalued.
Does Adagio Medical Holdings pay dividends?
Adagio Medical Holdings does not currently pay dividends.
What is Adagio Medical Holdings’s EPS estimate?
Adagio Medical Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Adagio Medical Holdings have?
Adagio Medical Holdings has 22,210,459 shares outstanding.
What happened to Adagio Medical Holdings’s price movement after its last earnings report?
Adagio Medical Holdings reported an EPS of -$0.21 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Adagio Medical Holdings?
Currently, no hedge funds are holding shares in ADGM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adagio Medical Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (224.07% Upside)
$3.50 (224.07% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.65%
12-Months-Change
Fundamentals
Return on Equity
-312.04%
Trailing 12-Months
Asset Growth
-9.89%
Trailing 12-Months
Company Description
Adagio Medical Holdings
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
ADGM Stock 12 Month Forecast
Average Price Target
$3.50
▲(224.07% Upside)
Technical Analysis
Co-Diagnostics
―
PAVmed
―
Vivos Therapeutics
―
Inspira Technologies Oxy BHN
―
Envoy Medical
―